FINWIRES · TerminalLIVE
FINWIRES

Amazon-Backed Anthropic's Mythos Accessible to European Union

By

Amazon (AMZN)-backed Anthropic's Mythos AI model is now accessible to the European Union Agency for Cybersecurity ahead of its release, the agency confirmed Wednesday in an emailed response to.

"Our priority now is to continue working with Anthropic to agree on the terms and conditions of the future access," the agency said.

The agency added that a "new wave" of powerful AI tools is coming to the market and it is in discussions related to other "Frontier" AI models.

Mythos is an AI model capable of identifying and exploiting vulnerabilities in operating systems and web browsers, Anthropic said in April.

Price: $253.94, Change: $-2.58, Percent Change: -1.01%

Related Articles

Wire

MAIA Gets FDA Clearance for Enrollment in Expanded Phase 2 Cancer Study

MAIA Biotechnology (MAIA) said Wednesday it has received clearance from the US Food and Drug Administration to open enrollment for the expansion of the phase 2 THIO-101 trial of ateganosine for advanced non-small cell lung cancer.The firm said it obtained clearance of its updated investigational new drug application highlighting improved manufacturing capabilities, including new manufacturers and formulation.In addition to the US, the THIO-101 study is ongoing at 44 clinical sites in six countries, it added.The additional data from the expansion studies may further support a filing for an accelerated approval, MAIA said.Shares were up over 4% in morning trading.Price: $1.41, Change: $+0.06, Percent Change: +4.44%

$MAIA
Wire

Comcast NBCUniversal to Break Ground on First Euro Theme Park Resort 'Soon' in UK

Comcast (CMCSA) NBCUniversal said Wednesday it will soon begin construction on its first European theme park and resort, the Universal United Kingdom Resort, in Bedford, England.The resort will include a theme park with multiple immersive lands and attractions, a 500-room hotel, and a retail, dining and entertainment complex.Price: $24.56, Change: $-0.30, Percent Change: -1.19%

$CMCSA
Wire

Alpha Tau Medical, Tolmar International Agree to Develop, Commercialize Prostate Cancer Therapy

Alpha Tau Medical (DRTS) and Tolmar International have agreed to develop and commercialize Alpha DaRT therapy for the treatment of prostate cancer in the US, the companies said Wednesday.Under the agreement, Alpha Tau will lead clinical development and manufacture the therapy, while Tolmar International will receive exclusive rights it in the US, according to the companies.Additionally, the companies said Tolmar International will make a $20 million equity investment in Alpha Tau at $11.99 per share and provide $15 million towards a new US manufacturing facility.The deal also includes up to $96.5 million in development and regulatory milestones and up to $65 million in commercial milestone payments for the initial indication, Alpha Tau Medical and Tolmar International said.Alpha Tau said it will sell Alpha DaRT to Tolmar at 60% of onward net sales price, subject to certain adjustments.Alpha Tau Medical shares were over 15% higher in early Wednesday trading.Price: $10.31, Change: $+1.38, Percent Change: +15.45%

$DRTS